Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • ImmuSignature MLR assay: rapid high-throughput assessment of therapeutic immunogenicity
mixed-lymphocyte-reaction-assay-appnote1920x640
Application Note

ImmuSignature MLR assay: rapid high-throughput assessment of therapeutic immunogenicity

This application note describes the properties of the mixed lymphocyte reaction (MLR) assay used by our preclinical services team as a rapid, relevant, and reliable platform to characterize the functionality of molecules of interest and address safety considerations.

It describes the importance of an MLR assay, how it can be applied to biologics and small molecules, and shows data that demonstrates the assay's suitability, scalability and flexibility.

For research use only. Not for use in diagnostic procedures.

Download Resource

ImmuSignature MLR assay: rapid high-throughput assessment of therapeutic immunogenicity

Download Application Note
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.